MedPath

The effectiveness of Siddha and Allopathic treatment as reported by clinicians and patients

Not yet recruiting
Conditions
Psoriasis vulgaris,
Registration Number
CTRI/2020/01/022884
Lead Sponsor
Melaka Manipal Medical College
Brief Summary

This is a prospective cohort study comparing clinical and patient-reported outcomes in two groups, Siddha standard of care and allopathic standard of care in 192 patients ( 96 patients in each group) with psoriasis. This study has been approved by the Kasturba Medical College and Kasturba Hospital Institutional ethics Committee and patients will be recruited only after taking the informed consent. This will be done in the Department of Dermatology, Venereology and Leprosy, Kasturba Hospital, MAHE, Manipal and Division of Siddha, Center for Integrative Medicine and Research (CIMR), MAHE, Manipal. Patients in both the groups will be observed till 4 months of treatment or till the attainment of PASI 75 and from the fifth month up to 1-year, every month patients will be telephonically followed up. The primary outcome measure will be the number of patients reaching  PASI 75. Secondary outcome measures will be the number of relapses in each patient, the number of patients with different grades of remission, time taken to achieve a different grade of remission, duration of remission, assessment of adverse drug reactions, improvement in the patient-reported outcome scores, cost-effectiveness ratio, change in the cytokine levels at the attainment of PASI 75 compared to the baseline level.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
192
Inclusion Criteria

1.Patients with PASI score >10 2.Patient with Psoriasis Vulgaris (plaque psoriasis) and palmoplantar type of psoriasis 3.Patients with no systemic therapy for the past four weeks or topical therapy for the past two weeks.

Exclusion Criteria

1.Pregnant and lactating women 2.Coexisting eczema or lichen planus 3.Patients on any systemic drugs known to exacerbate psoriasis 4.Patients who are on any other treatment for psoriasis.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of patients reaching PASI 75 (75% improvement in the PASI score)0,1,2,3,4 months
Secondary Outcome Measures
NameTimeMethod
Number of relapses in each patientNumber of patients with different grades of remission

Trial Locations

Locations (1)

Department of Dermatology, Venereology and Leprosy and Division of Siddha

🇮🇳

Udupi, KARNATAKA, India

Department of Dermatology, Venereology and Leprosy and Division of Siddha
🇮🇳Udupi, KARNATAKA, India
Dr Arul Amuthan
Principal investigator
9986353238
arul.amuthan@manipal.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.